EORTC-22996-24002-ROG-HNCG

A phase III double-blind, randomized, placebo-controlled study of Erythropoietin when used as an adjuvant to radiation therapy in patients with head and neck squamous cell carcinoma. EORTC 22996-24002
Trial StatusAll trial activities ended
DatesDate of activation: 12-Mar-01
Closed on : 04-Apr-03
Data management at EORTCFull
Phase3
Randomized trialYes
TypeAdjuvant
Targeted Sample size762
Number of steps1
Drug
Study Staff
Type of cancerHead and Neck
Participating Groups
Protocol summaryClinicalTrials.gov
NCT numberNCT00017277
EudraCT